Pieris Pharmaceuticals (NASDAQ:PIRS) Announces Earnings Results

Pieris Pharmaceuticals (NASDAQ:PIRS) issued its earnings results on Monday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18, Fidelity Earnings reports. Pieris Pharmaceuticals had a negative return on equity of 114.25% and a negative net margin of 147.19%. The business had revenue of $15.13 million during the quarter, compared to analysts’ expectations of $6.28 million.

Shares of NASDAQ PIRS traded down $0.12 during trading on Tuesday, reaching $3.83. The company had a trading volume of 10,696 shares, compared to its average volume of 497,449. The company’s fifty day moving average price is $3.53 and its 200-day moving average price is $4.20. Pieris Pharmaceuticals has a 12 month low of $2.39 and a 12 month high of $6.04. The stock has a market cap of $192.63 million, a P/E ratio of -7.90 and a beta of 1.26.

PIRS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Pieris Pharmaceuticals in a report on Monday. Robert W. Baird cut Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a report on Tuesday, July 30th. ValuEngine cut Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Zacks Investment Research raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Saturday. Finally, William Blair reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.42.

In other Pieris Pharmaceuticals news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $4.50, for a total value of $225,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 6.59% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: Are all No-Load Funds Equal?

Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit